Evidence map›Paper›PMID 25003939›Full record

ArticlePloS one2014

HIV-1 pol diversity among female bar and hotel workers in Northern Tanzania.

Ireen E Kiwelu, Vladimir Novitsky, Elimsaada Kituma, Lauren Margolin, Jeannie Baca, Rachel Manongi, Noel Sam, John Shao, Mary F McLane, Saidi H Kapiga and 1 more

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ireen E KiweluKilimanjaro Christian Medical Centre and College, Tumaini University, Moshi, Tanzania; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Vladimir NovitskyDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Elimsaada KitumaKilimanjaro Christian Medical Centre and College, Tumaini University, Moshi, Tanzania; Kilimanjaro Reproductive Health Program, Moshi, Tanzania.
Lauren MargolinDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Jeannie BacaDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Rachel ManongiKilimanjaro Christian Medical Centre and College, Tumaini University, Moshi, Tanzania; Kilimanjaro Reproductive Health Program, Moshi, Tanzania.
Noel SamKilimanjaro Christian Medical Centre and College, Tumaini University, Moshi, Tanzania; Kilimanjaro Reproductive Health Program, Moshi, Tanzania.
John ShaoKilimanjaro Christian Medical Centre and College, Tumaini University, Moshi, Tanzania.
Mary F McLaneDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Saidi H KapigaLondon School of Hygiene and Tropical Medicine, London, United Kingdom; Kilimanjaro Reproductive Health Program, Moshi, Tanzania.
M EssexDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America.

Funding

INTERNATIONAL TRAINING IN AIDS-RELATED EPIDEMIOLOGYD43TW000004 · FIC · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 1988 to 2012
$13.4M
FIC NIH HHS D43 TW000004
6 · The paper itself

Abstract

A national ART program was launched in Tanzania in October 2004. Due to the existence of multiple HIV-1 subtypes and recombinant viruses co-circulating in Tanzania, it is important to monitor rates of drug resistance. The present study determined the prevalence of HIV-1 drug resistance mutations among ART-naive female bar and hotel workers, a high-risk population for HIV-1 infection in Moshi, Tanzania. A partial HIV-1 pol gene was analyzed by single-genome amplification and sequencing in 45 subjects (622 pol sequences total; median number of sequences per subject, 13; IQR 5-20) in samples collected in 2005. The prevalence of HIV-1 subtypes A1, C, and D, and inter-subtype recombinant viruses, was 36%, 29%, 9% and 27%, respectively. Thirteen different recombination patterns included D/A1/D, C/A1, A1/C/A1, A1/U/A1, C/U/A1, C/A1, U/D/U, D/A1/D, A1/C, A1/C, A2/C/A2, CRF10_CD/C/CRF10_CD and CRF35_AD/A1/CRF35_AD. CRF35_AD was identified in Tanzania for the first time. All recombinant viruses in this study were unique, suggesting ongoing recombination processes among circulating HIV-1 variants. The prevalence of multiple infections in this population was 16% (n = 7). Primary HIV-1 drug resistance mutations to RT inhibitors were identified in three (7%) subjects (K65R plus Y181C; N60D; and V106M). In some subjects, polymorphisms were observed at the RT positions 41, 69, 75, 98, 101, 179, 190, and 215. Secondary mutations associated with NNRTIs were observed at the RT positions 90 (7%) and 138 (6%). In the protease gene, three subjects (7%) had M46I/L mutations. All subjects in this study had HIV-1 subtype-specific natural polymorphisms at positions 36, 69, 89 and 93 that are associated with drug resistance in HIV-1 subtype B. These results suggested that HIV-1 drug resistance mutations and natural polymorphisms existed in this population before the initiation of the national ART program. With increasing use of ARV, these results highlight the importance of drug resistance monitoring in Tanzania.

Indexed as

AdultAnti-HIV AgentsDNA Mutational AnalysisDrug Resistance, ViralFemaleHIV-1HIV InfectionsHumansMolecular Sequence DataMutationPhylogenypol Gene Products, Human Immunodeficiency VirusPolymorphism, GeneticProspective StudiesTanzaniaAnti-HIV Agentspol Gene Products, Human Immunodeficiency Virus

Identifiers

PMID25003939
PMCPMC4087014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.